ArticleKidney international reports2024

Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.

Romy N Bouwmeester et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.